Please provide your email address to receive an email when new articles are posted on . In the VOYAGER PAD trial, patients with symptomatic peripheral artery disease who underwent lower-extremity ...
The addition of clopidogrel to rivaroxaban (Xarelto; Bayer/Janssen) and aspirin in patients with a recent lower limb revascularization does not provide increased protection against acute limb ischemia ...
Revascularization is a procedure that can restore blood flow in blocked arteries or veins. For someone with peripheral artery disease (PAD), the operation can help ease symptoms and prevent serious ...
Xarelto, a Factor Xa inhibitor, is currently indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Janssen announced positive results from the ...
Following an emergency lower limb revascularization, people with PAD who are in their 50s have a higher risk than those in their 80s of needing major amputation, according to a large analysis of ...
RARITAN, N.J., May 16, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO ® (rivaroxaban) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback